AAM and Biosimilars Council praise FDA plan to simplify biosimilar development
FDA draft guidance removes redundant PK testing requirements where scientifically rigorous data already exists.
AAM
AAM highlights Board Chair Bob Hoffman in new profile
Hoffman emphasized what he called a return to fundamentals for the industry, highlighting disciplined execution, competition, and collaboration as key to long-term sustainability.
AAM’s John Murphy III testifies before Congress on lowering health care costs and the Rx drug supply chain
Outlines four key policy areas Congress can act on now to protect generic and biosimilar medicines and provide access and savings for patients.
Bob Hoffman named chair of the Association for Accessible Medicines Board of Directors
“It is an honor to serve as AAM board chair, and I thank the board for the privilege,” said Bob Hoffman.
Over 36 groups join the Biosimilars Council and AAM to reiterate support for interchangeability legislation
Call for passage of Biosimilar Red Tape Elimination Act.
2026 Health Care Outlook: John Murphy III, AAM
By John Murphy III, president and CEO of the Association for Accessible Medicines
AAM applauds Q1/Q2 House bill passage
Cuts red tape, brings patient faster access to lower-cost medicines.
AAM and the Biosimilars Council praise FDA announcement on biosimilars clinical efficacy studies and interchangeability
FDA Commissioner Makary joined AAM’s GRx+Biosims 2025 conference today.
AAM requests federal injunction to block Connecticut’s unconstitutional drug price law
Generic pharmaceutical trade group steps in to protect patient access to affordable generic drugs.
AAM pushes back on Colorado drug price cap
AAM President John Murphy III noted that prices for generic and biosimilar medicines keep falling, yet no biosimilar for Enbrel is available in the U.S.
AAM praises Q1/Q2 House bill markup
The bipartisan, bicameral legislation was included in the 2024 year-end spending bill and reintroduced in this Congress.
AAM report: $467B saved by generics and biosimilars in 2024
The Association for Accessible Medicines states that lower-cost drugs saved $3.4 trillion over the past decade but warns that regulatory and pricing pressures threaten the market's long-term viability.
AAM congratulates Dr. Tidmarsh on appointment as CDER director
“We look forward to a collaborative partnership with Dr. Tidmarsh and the larger team at CDER to prioritize regulatory efficiency.”
Medicare drug price negotiation may harm generic and biosimilar development, warns report.
The paper concludes that, although the negotiation program might reduce drug costs initially, it could threaten the long-term sustainability of the generics and biosimilars market, a key driver of lower prescription costs.
Patent thickets and litigation abuses hinder all biosimilars
White paper analyzes problems and solutions to patent abuses.
Groups join the Biosimilars Council and AAM letter of support for interchangeability legislation
39 Groups support the Biosimilar Red Tape Elimination Act.